Patient description: A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Heart Failure Subject is male 2. Subject is aged between 18 and 50 years inclusive. 3. Subject has given signed informed consent. 4. Subject's Body Mass Index (BMI) is between 18 and 30 kg/m2 inclusive. 5. Subject weighs less than 100 kg. 6. Subject is considered to be in good health in the opinion of the investigator, as determined by: 1. A pre-study physical examination with no clinically significant abnormalities. 2. Vital signs within normal ranges (supine after 3 minutes rest heart rate: 40 to 80 bpm; systolic BP: 100 to 140 mmHg; diastolic BP: 50-90 mmHg; respiration rate: 8 to 18 breaths per minute; oxygen saturation: 96-100%) 3. An ECG with no clinically significant abnormalities. 7. Subject's pre-study clinical laboratory findings are within normal range or if outside of the normal range not deemed clinically significant in the opinion of the investigator. 8. Cardiac troponin I is less than the upper limit of the laboratory reference range. 9. A screening echocardiogram demonstrates normal cardiac function, an ejection fraction of between 40% and 70% with no significant valvular regurgitation (grade 1) and/or stenosis and images are deemed to be of good quality by the sonographer  Subject has had a clinically significant illness in the four weeks before screening. 2. Use of prescribed mediations in the 3 weeks prior to dosing or over-the-counter preparations (including vitamin supplements and herbal remedies) for 7 days prior to dosing, except paracetamol which will be allowed up to 48 hours prior to dosing. 3. Subject has a significant history of drug/solvent abuse or a positive drugs of abuse test at screening. 4. Subject with a history of alcohol abuse or currently drinks in excess of 28 units per week. 5. Subject smokes more than 5 cigarettes (or equivalent) per day. 6. Subject is not willing to refrain from caffeine/xanthine containing products from 48 hours prior to the screening medical and admission on Day -1 until the post study medical. 7. Subject is in the opinion of the investigator not suitable to participate in the study. 8. Subject who has participated in any clinical study with an investigational drug/device within three months prior to the first day of dosing. 9. Subject who has a positive result of HIV screen, Hepatitis B screen or Hepatitis C screen. 10. Subject has had a serious adverse reaction or significant hypersensitivity to any drug. 11. Subject has donated 500 ml or more of blood within the month prior to screening. 12. Subject has a history of cardiovascular disease or family history of premature cardiovascular disease or death